Version of section 95 from 2018-06-27 to 2018-10-16:
The following provision is not in force.
Marginal note:Dissolution and disintegration
95 Each discrete unit of a cannabis product that is intended to be administered orally, rectally or vaginally must meet the requirements of a dissolution or disintegration test that is applicable to its formulation and that is set out in any publication referred to in Schedule B to the Food and Drugs Act.
- Date modified: